Symposium ArticleStructural Bone Changes in pondyloarthritis: Mechanisms Clinical Impact and Therapeutic Considerations
Section snippets
THE RELATION OF INFLAMMATION TO STRUCTURAL DAMAGE
“Low inflammation leads to low structural damage” is the concept we have learned from RA. At first sight, this concept holds true for SpA. A tighter therapeutic regimen with continuous use of nonsteroidal anti-inflammatory drugs is more effective in retarding structural progression in SpA than a more “laissez-faire” strategy that allows nonsteroidal anti-inflammatory drugs only on demand.1 This concept, however, is challenged by the failure of all 3 approved tumor necrosis factor (TNF)
LYMPHOCYTES AND THE ROLE OF OSTEOCLASTS IN INFLAMMATION
Accumulation of lymphocytes in the bone marrow is likely to be the reason for the generation of osteoclasts, because activated lymphocytes are the primary source of receptor activator of nuclear factor kappa-B ligand, a molecule that drives osteoclast differentiation. Vertebral osteoporosis and resorption of trabecular bone thus seems to be the direct consequence of inflammation. This notion highlights a major difference between SpA and RA: in SpA, the bone tissue directly exposed to
ANABOLIC CHANGES AND THE PATHOPHYSIOLOGY OF SPA
Anabolic changes leading to syndesmophyte formation and ankylosis in SpA are of particular interest in understanding the pathophysiology of the disease. Current concepts suggest that, in patients with SpA, both mechanical triggers (enthesial stress) and inflammatory triggers (enthesitis) lead to mesenchymal tissue responses associated with the formation of new bone that bridges the intervertebral spaces, the small facet joints of the spine and the sacroiliac joints. Formation of bony spurs
TREATMENT STRATEGIES
The recent data on DKK-1 and sclerostin suggest that Wnt activation may be a decisive step in the formation of ankylosis in patients with SpA. Blocking of Wnt signals could thus represent an interesting strategy to inhibit ankylosis; however, this strategy bears the risk of generalized bone loss and osteoporosis, because it would likely inhibit bone formation in general. Specific strategies to block periosteal bone formation without affecting trabecular bone remain to be determined. Such
CONCLUSION
In summary, syndesmophytes in SpA are based on the differentiation of periosteal bone lining cells into osteoblasts leading to the deposition of new bone. This process, which results in ankylosis, is triggered by factors that support the differentiation of mesenchymal cells into osteoblasts. Prostaglandins such as prostaglandin E2, Wnt proteins and BMPs seem to be key signals, are responsible for bony overgrowth in SpA and constitute promising targets to halt structural changes in SpA.
REFERENCES (15)
- et al.
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial
Arthritis Rheum
(2005) - et al.
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis
Arthritis Rheum
(2008) - et al.
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept
Arthritis Rheum
(2008) - et al.
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
Arthritis Res Ther
(2009) - et al.
From bone biology to clinical outcome: state of the art and future perspectives
Ann Rheum Dis
(2010) - et al.
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis
Arthritis Rheum
(2006) - et al.
Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in longstanding ankylosing spondylitis
Ann Rheum Dis
(2009)
Cited by (33)
Pathogenesis of psoriatic arthritis
2021, Best Practice and Research: Clinical RheumatologyCitation Excerpt :In the following section, we focus on how innate and adaptive immune cells and the mediators they produce interact with FLS, bone cells and cartilage to result in the characteristic structural changes observed in PsA (Fig. 2). The immune-bone cell interactions that contribute to osteo-proliferation, osteoporosis, and bone and cartilage damage are central to the aetiopathogenesis of PsA, and are targets not only for therapeutic intervention but also for predicting which patients may develop significant structural damage [60]. Bone remodelling is orchestrated by osteoblasts, osteocytes and osteoclasts, and regulated by hormones, cytokines and locally produced signalling molecules influenced by mechanical stimuli (summarised in Fig. 2).
Trabecular bone loss contributes to radiographic spinal progression in patients with axial spondyloarthritis
2020, Seminars in Arthritis and RheumatismCitation Excerpt :Reduced bone strength triggers anabolic reactions aimed at stabilization, which results in new bone formation. The trabecular and cortical compartments appear to have different reactions to inflammation; in axSpA, inflammation has a direct effect on the trabecular bone of the vertebrae but not on the cortical bone [6]. Because persistent inflammation in the trabecular bone of the vertebral bodies may prevent the anabolic response from correcting instability, formation of new cortical bone may increase [5].
Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis
2014, International ImmunopharmacologyCitation Excerpt :The tumour necrosis factor-alpha (TNF-α) seems to play the most important role in the inflammatory response to SpA [4,6,7], and the use of anti-TNF-α medication contributes significantly in improving the inflammatory condition, thus promoting a better quality of life and increasing the likelihood of survival for these patients [6,8]. Furthermore, several molecules appear to contribute to new bone formation in patients with AS, such as bone-specific alkaline phosphatase (BAP) and osteocalcin [9–12]. BAP is an important bone growth biomarker.
Relationship between trabecular bone score, bone mineral density and vertebral fractures in patients with axial spondyloarthritis
2023, BMC Musculoskeletal DisordersSpondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies
2023, Nature Reviews Rheumatology
This study was supported by the Deutsche Forschungsgemeinschaft (FG 661/TP4 and SPP1468-IMMUNOBONE), the Bundesministerium für Bildung und Forschung (BMBF; projects ANCYLOSS and IMMUNOPAIN) and the MASTERSWITCH, KINACEPT, IMI and ADIPOA projects of the European Union.
Presented at the annual research and education meeting of Spondyloarthritis Research and Treatment Network (SPARTAN), Houston, Texas, July 23–24, 2010.